In mice with and without multiple endocrine neoplasia 1 (MEN1), anti-VEGF therapy reduces tumor size, prolactin secretion, and vascularity in prolactin-secreting adenomas [40,41,42] as well as normalizing blood vessels and reducing intra-tumoral hemorrhage [42]. The gene discussed is PRL; the disease is multiple endocrine neoplasia type 1.